PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, initially intended to treat chronic and acute wounds, today unveiled an expanded regulatory/commercial pipeline for its Microcyn-based products as preparation for the company’s CEO and founder, Hoji Alimi, to provide even greater detail at the OneMedForum on January 12, 2010 in San Francisco.
